Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress

Publisher： Bentham Science Publishers

E-ISSN： 1873-4316|13|9|1842-1851

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.13, Iss.9, 2012-07, pp. : 1842-1851

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recent Clinical Experience with Oncolytic Viruses

By  

Current Pharmaceutical Biotechnology, Vol. 13, Iss. 9, 2012-07 ,pp. : 1834-1841

Bentham Science Publishers

Access to resources Recommend Favorite

Oncolytic Virotherapy for Breast Cancer Treatment

By  

Current Gene Therapy, Vol. 18, Iss. 4, 2018-08 ,pp. : 192-205

Bentham Science Publishers

Access to resources Recommend Favorite

Phase 1 Clinical Experience Using Intravenous Administration of PV701, an Oncolytic Newcastle Disease Virus

By  

Current Cancer Drug Targets, Vol. 7, Iss. 2, 2007-03 ,pp. : 157-167

Bentham Science Publishers

Access to resources Recommend Favorite

Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets

By Halldén Gunnel   Portella Giuseppe  

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 10, 2012-10 ,pp. : 945-958

Informa Healthcare

Access to resources Recommend Favorite

Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers

By  

Current Cancer Drug Targets, Vol. 18, Iss. 2, 2018-01 ,pp. : 188-201

Bentham Science Publishers

Access to resources Recommend Favorite